Sign in to view content

Results from Part 1 of the Phase 2/3 SIGLEC Trial Assessing AVD-104 for Geographic Atrophy: Glyco-immunologic Modulation of Macrophage Activity

Rishi P. Singh, MD

Video
Published 2024

Related

Baseline Characteristics in the Phase 2 GOLDEN Study of IONIS-FB-LRx, an Investigational Antisense Oligonucleotide Designed to Treat AMD-Associated Geographic Atrophy
Glenn J. Jaffe, MD
Annual Meeting Talks
2022
Learnings From the Lampalizumab Chroma and Spectri Phase 3 Trials: Effect of Baseline Characteristics on Geographic Atrophy Progression
Carl D. Regillo, MD
Annual Meeting Talks
2018
Agitation of the Syringe as a Cause of Inflammation After Intravitreal Injection of Aflibercept: A Randomized, Double-blind, Controlled Clinical Trial
Gustavo Barreto de Melo, MD, PhD, FASRS
Annual Meeting Talks
2020

Category: AMD-Non-Neovascular

See more